LCB02A for Cancer

This trial tests a new treatment called LCB02A, a potential drug for advanced solid tumors that resist current treatments. The goal is to determine the right dose and assess its effectiveness on specific tumor types. The trial has two phases: first, to identify the safest dose, and then to evaluate its effectiveness on selected tumors. Suitable participants have advanced solid tumors unresponsive to standard treatments and are Claudin 18.2 positive, a specific protein found in some cancers. Participants should also have stable health conditions and be willing to provide tumor samples for study purposes. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new drug.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor to get a clear answer.

Previous studies found that LCB02A, an antibody-drug conjugate (ADC), was well tolerated. ADCs target specific proteins on cancer cells, and LCB02A targets a protein called Claudin 18.2, present in some solid tumors such as those in stomach and pancreas cancers. Research has shown that LCB02A does not cause severe side effects for most patients, indicating promising safety. Although still under study, the treatment has demonstrated a strong safety profile, with most side effects being manageable.¹²³⁴⁵

LCB02A is unique because it targets cancer cells with a new mechanism of action that differs from standard chemotherapy and immunotherapy treatments. Unlike traditional approaches that often affect both healthy and cancerous cells, LCB02A is designed to selectively attack cancer cells, potentially reducing side effects and improving patient outcomes. Researchers are excited about LCB02A because its targeted approach may offer a more effective and less toxic treatment option for cancer patients, especially those who have not responded well to existing therapies.

Studies have shown that LCB02A, a type of targeted therapy, can effectively attack certain cancer cells. Research indicates that LCB02A targets a protein called Claudin 18.2, often found in cancers such as stomach and pancreatic tumors. In lab tests, LCB02A demonstrated strong effects against tumors and killed cancer cells. Animal studies showed promising results, reducing tumor size in models of stomach and pancreatic cancer. Initial findings suggest that LCB02A could effectively treat these cancers. Participants in this trial will receive LCB02A monotherapy to further evaluate its effectiveness.²⁴⁵⁶⁷